Concepedia

Author

Mark Rutstein

Amgen (United States)

Also Known As

M. D. Rutstein, M. Rutstein, M.D. Rutstein, Mark D. Rutstein, Mark Daniel Rutstein, Mark Rutstein

31

Publications

1.7K

Citations

9

H-Index

19

Concepts

All Affiliations

Amgen (United States)Harvard UniversityMcLean Hospital
MR

About

Mark Rutstein is an author at Amgen (United States) specializing in medicine, renal pharmacology, and chronic kidney disease.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

609

2

Social Sciences

1

1

473

3

Cognitive Science

1

1

473

4

Nephrology

1

1

136

5

Neuroscience

1

1

473

Mark Rutstein

×

9

Publications

1.6K

Citations

9

H-Index

YearCitations

Dopamine receptor pruning in prefrontal cortex during the periadolescent period in rats

Susan L. Andersen, Andrew T. Thompson, Mark Rutstein,

Synapse

2000

473

Sex differences in dopamine receptor overproduction and elimination

Susan L. Andersen, Mark Rutstein, J Benzo,

Neuroreport

1997

318

Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database

W. Marieke Schoonen, Gena Kucera, Jenna E. Coalson,

British Journal of Haematology

2009

297

Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim

David J. Kuter, Ghulam J. Mufti, Barbara J. Bain,

Blood

2009

183

Pharmacoepidemiology of Anemia in Kidney Transplant Recipients

Wolfgang C. Winkelmayer­, Reshma Kewalramani, Mark Rutstein,

Journal of the American Society of Nephrology

2004

136

ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer

Guru Sonpavde, Andrea Necchi, Shilpa Gupta,

Future Oncology

2019

90

Evaluating clinically meaningful change on the ITP-PAQ: preliminary estimates of minimal important differences

Susan D. Mathias, Sue Gao, Mark Rutstein,

Current Medical Research and Opinion

2008

32

Molecular subtypes and outcomes in regorafenib-treated patients with metastatic colorectal cancer (mCRC) enrolled in the CORRECT trial.

Michael Teufel, Susanne Schwenke, Henrik Seidel,

Journal of Clinical Oncology

2015

26

Long-Term Safety Profile of Romiplostim in Patients with Chronic Immune Thrombocytopenia (ITP).

Howard A. Liebman, David Henry, François Lefrère,

Blood

2008

10

Page 1